January 22, 2020 08:58 AM EST

Transitional leaders take charge as FDA begins PhIII of OND reorganization

The FDA on Tuesday officially began Phase III of its Office of New Drugs (OND) reorganization after a short delay, and several leaders of the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tran­si­tion­al lead­ers take charge as FDA be­gins PhI­II of OND re­or­ga­ni­za­tion